<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386503</url>
  </required_header>
  <id_info>
    <org_study_id>ARAMF_L_01570</org_study_id>
    <nct_id>NCT00386503</nct_id>
  </id_info>
  <brief_title>Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed &amp; Fasted Conditions</brief_title>
  <official_title>A Randomized, Open-Label, Cross-Over Study, to Compare the Bioavailability of the Fixed Combination of Amodiaquine and Artesunate (COARSUCAM™) After Single Oral Administration Under Fed and Fasted Conditions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      -  Primary Objective: to evaluate the interaction with food after a single oral dose of a
           fixed combination of amodiaquine (AQ) and artesunate (AS) (COARSUCAM™) in healthy male
           subjects

        -  Secondary Objective: to assess the clinical and biological safety and tolerability of
           Coarsucam™
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics/Time course of the plasma concentrations of AS, AQ &amp; their pharmacologically active metabolites dihydroartemisinin (DHA) &amp; desethylamodiaquine (DSA), used to determine:Tmax, Cmax, t1/2, AUC(0-t) &amp; AUC(0-Inf) for AS, DHA &amp; AQ</measure>
    <time_frame>During all the study conduct</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax, Cmax, Truncated AUC(0-10d) for DSA</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability/Adverse events, physical examinations, vital signs including heart rate and blood pressure, ECG and laboratory parameters.</measure>
    <time_frame>From the signature of the informed consent up to the end of the study</time_frame>
  </secondary_outcome>
  <enrollment>22</enrollment>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate + Amodiaquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian subjects

          -  Weight between 50 kg and 90 kg. 18 ≤ Body Mass Index ≤ 28 kg/m2.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Lameyre</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>December 8, 2008</last_update_submitted>
  <last_update_submitted_qc>December 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

